Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of imiquimod topical therapy for Bowen's disease
jRCTs041230132Recruiting
- Start
- Nov 2024
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imiquimod in Bowen disease (BD). Primary endpoint: Tumor shrinkage rate at the end of protocol treatment. Started Nov 2024; status: recruiting.
02
Drugs
imiquimod
03
Conditions
Bowen disease (BD)
Beyond the preview
Go deeper on jRCTs041230132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230132.